Scott Requadt is Chief Executive Officer of Tourmaline Bio Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
ESSA Pharma Inc.
28 Mar 24
4
ESSA Pharma Inc.
16 Jan 24
4
Talaris Therapeutics, Inc.
6 Jul 23
144
Talaris Therapeutics, Inc.
5 Jul 23
4
Talaris Therapeutics, Inc.
3 Feb 23
4
ESSA Pharma Inc.
1 Nov 22
4
Talaris Therapeutics, Inc.
13 Sep 22
4
Talaris Therapeutics, Inc.
2 Aug 22
4
Talaris Therapeutics, Inc.
28 Jul 22
4
Talaris Therapeutics, Inc.
26 Jul 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | EPIX Essa Pharma | Options Common Shares | Grant | Acquire A | No | No | 9.04 | 50,000 | 452.00 k | 50,000 |
6 Nov 23 | EPIX Essa Pharma | Common Shares | Other | Dispose J | No | No | 0 | 12,500 | 0.00 | 30,002 |
30 Oct 23 | EPIX Essa Pharma | Common Shares | Other | Dispose J | No | No | 0 | 17,502 | 0.00 | 42,502 |
1 Feb 23 | TRML Tourmaline Bio | Stock Appreciation Right Common Stock | Grant | Acquire A | No | No | 1.73 | 320,000 | 553.60 k | 320,000 |
1 Feb 23 | TRML Tourmaline Bio | Stock Option Common Stock | Grant | Acquire A | No | No | 1.73 | 320,000 | 553.60 k | 320,000 |
30 Dec 22 | TRML Tourmaline Bio | Common Stock | Grant | Acquire A | No | No | 0.867 | 4 | 3.47 | 590,193 |